Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase: Enrolling; Early Phase 1

Conditions: Healthy Human; Lung Cancer

Treatments: Drug: 68Ga-A3

Study type: Interventional

Funder types: Other

Identifiers

NCT06194630

PekingUMCH ACE2 68Ga-A3

Details and patient eligibility

About

In the past three years, as the key protein suggested to be involved in host cell entry of SARS-CoV-2, studies of ACE2 aroused people's attention again. Tracking the expression of ACE2 in vivo is crucial to further understanding of COVID-19, dynamically monitoring the effect of antiviral therapy and the development of related vaccines. It is also expected to further conduct in-depth research on the physiological effects of ACE2 and RAAS, and the mechanism of ACEI/ARB (32). With the development of both molecular imaging agents and related equipment, several ACE2-targeting PET imaging agents have been investigated based on different strategies while some of them were tested in clinical trials. The aim of this study was to intercept key ACE2-binding sites from coronavirus RBD and test their potential as ACE2-targeting PET agents.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• the ability to provide informed written consent
• a medical history without any ACE2-related comorbidities

Exclusion criteria

• liver and renal function dysfunction,
• pregnancy or current lactation

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

68Ga-A3

Experimental group

Description:

Within 1 week, each participant underwent PET/CT scan after intravenous administration of 68Ga-A3

Treatment:

Drug: 68Ga-A3